Search by Drug Name or NDC

    NDC 00113-9007-26 Good Sense Severe Tussin CF Max 650; 20; 400; 10 mg/20mL; mg/20mL; mg/20mL; mg/20mL Details

    Good Sense Severe Tussin CF Max 650; 20; 400; 10 mg/20mL; mg/20mL; mg/20mL; mg/20mL

    Good Sense Severe Tussin CF Max is a ORAL SOLUTION in the HUMAN OTC DRUG category. It is labeled and distributed by L. Perrigo Company. The primary component is ACETAMINOPHEN; DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN; PHENYLEPHRINE HYDROCHLORIDE.

    Product Information

    NDC 00113-9007
    Product ID 0113-9007_987b2abc-adc8-4383-87dc-52392dd8af47
    Associated GPIs
    GCN Sequence Number n/a
    GCN Sequence Number Description n/a
    HIC3 n/a
    HIC3 Description n/a
    GCN n/a
    HICL Sequence Number n/a
    HICL Sequence Number Description n/a
    Brand/Generic n/a
    Proprietary Name Good Sense Severe Tussin CF Max
    Proprietary Name Suffix n/a
    Non-Proprietary Name Acetaminophen, dextromethorphan HBr, guaifenesin, phenylephrine HCl
    Product Type HUMAN OTC DRUG
    Dosage Form SOLUTION
    Route ORAL
    Active Ingredient Strength 650; 20; 400; 10
    Active Ingredient Units mg/20mL; mg/20mL; mg/20mL; mg/20mL
    Substance Name ACETAMINOPHEN; DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN; PHENYLEPHRINE HYDROCHLORIDE
    Labeler Name L. Perrigo Company
    Pharmaceutical Class Adrenergic alpha1-Agonists [MoA], Decreased Respiratory Secretion Viscosity [PE], Expectorant [EPC], Increased Respiratory Secretions [PE], Sigma-1 Agonist [EPC], Sigma-1 Receptor Agonists [MoA], Uncompetitive N-methyl-D-aspartate Receptor Antagonist [EPC
    DEA Schedule n/a
    Marketing Category OTC MONOGRAPH FINAL
    Application Number part341
    Listing Certified Through 2024-12-31

    Package

    NDC 00113-9007-26 (00113900726)

    NDC Package Code 0113-9007-26
    Billing NDC 00113900726
    Package 1 BOTTLE in 1 CARTON (0113-9007-26) / 118 mL in 1 BOTTLE
    Marketing Start Date 2021-11-11
    NDC Exclude Flag N
    Pricing Information N/A

    Standard Product Labeling (SPL)/Prescribing Information SPL 987b2abc-adc8-4383-87dc-52392dd8af47 Details

    Revised: 3/2022